about
Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.Local intracerebral administration of Paclitaxel with the paclimer delivery system: toxicity study in a canine model.Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of thCalreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.Safety of conditioning agents for allogeneic haematopoietic transplantation.Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGelDo pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.Not too little, not too much-just right! (Better ways to give high dose melphalan).Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival.Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells.Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size.Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours.Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study
P2860
Q34046207-3E5C54E3-5DDC-45E6-A4B2-6C2F2279EAE2Q35127225-7AB20B64-8C5D-41D0-9570-16346A3155D5Q35586590-D44B3503-1860-4046-A1F7-B46BACE5A924Q36384780-636E7027-1282-4BCB-AAE0-EC5B9946208AQ37510948-C4923210-0140-49A7-9D24-DECBDC0F57B4Q37689187-3DB09ED7-73FD-4A1E-88DF-D4986C9771FCQ37834445-E4AC5BD1-F240-4602-8E2A-870A78302F80Q37863461-F22A1BD9-32CF-4794-ADFE-8E54600AB293Q38240941-0C854698-378B-4D63-8AB3-A01A5D474DF6Q39374803-7C0A22DC-DBF7-48C3-A2A5-6E781B9DF23FQ39763521-2D626C1A-B042-44E8-88C1-187F5DAA7BEAQ39793760-C928CF86-C275-440C-86B3-5AF86647E3B4Q43407581-56AA325E-3739-4944-9E0D-982D273705B9Q45174143-19993024-E04C-490F-BEB1-1D2381C68950Q46885001-1AC548B8-1100-41B0-9E19-195ACB535BE0Q47209459-E5C9D279-08DF-497F-A246-BA46CF1E2B65Q51146472-F59BC67F-3010-4274-8024-D7F806D3BB58Q57579466-862C9052-9FA8-410D-9D41-8E64958972B4
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacokinetics of high-dose chemotherapy.
@ast
Pharmacokinetics of high-dose chemotherapy.
@en
type
label
Pharmacokinetics of high-dose chemotherapy.
@ast
Pharmacokinetics of high-dose chemotherapy.
@en
prefLabel
Pharmacokinetics of high-dose chemotherapy.
@ast
Pharmacokinetics of high-dose chemotherapy.
@en
P2860
P356
P1476
Pharmacokinetics of high-dose chemotherapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704353
P407
P577
2004-02-01T00:00:00Z